Yarema Kristin 4
4 · ImageneBio, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
ImageneBio (IMA) CEO Kristin Yarema Receives Stock Award
What Happened
Kristin Yarema, CEO of ImageneBio, received two equity awards on March 16, 2026: 85,400 restricted stock units (RSUs) and 128,100 derivative shares (an option-style award). Both grants are listed at $0.00 acquisition price (i.e., they are compensation awards, not purchases). Total awarded shares equal 213,500. These are grants (code A), not sales or exercises.
Key Details
- Transaction date: 2026-03-16; Form 4 filed 2026-03-18 (appears timely — Form 4 is due within 2 business days).
- 85,400 RSUs acquired at $0.00 (footnote F1). RSUs convert to one share each upon settlement.
- 128,100 derivative shares acquired at $0.00 (footnote F2) — an option-style grant that vests over time.
- Vesting (F1): RSUs — 25% vest/settle on March 15, 2027; remaining balance vests in equal quarterly installments on the next 12 Standard Quarterly Dates (March 15, June 15, Sept 15, Dec 15).
- Vesting (F2): Option-style award — 25% vests on March 15, 2027; remaining shares vest in 36 substantially equal monthly installments (four-year schedule).
- Shares owned after transaction: Not specified in the provided filing.
- Transaction codes: A = Award/Grant; the 128,100 item is a derivative award (not an exercise).
Context
These are compensation grants to the CEO and do not involve a cash purchase or an immediate sale of shares. Grants are common for executive pay and are tied to continued service (and possibly performance); they do not necessarily signal a near-term market view. The option-style award has a multi-year vesting schedule and has not been exercised.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-16+85,400→ 85,400 total - Award
Employee Stock Option (right to buy)
[F2]2026-03-16+128,100→ 128,100 totalExercise: $6.20Exp: 2036-03-16→ Common Stock (128,100 underlying)
Footnotes (2)
- [F1]Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on March 15, 2027, and the balance will vest in successive equal quarterly installments on each of the next 12 Standard Quarterly Dates thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such vesting date. The "Standard Quarterly Dates" are each of March 15, June 15, September 15 and December 15.
- [F2]This option vests over four years, with 25% of the shares subject to this option vesting on March 15, 2027, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such vesting date.